Atlanta Catheter Therapies (ACT) has completed a $2.98m in Series A equity financing through an investment consortium in Chattanooga, TN.

The funds will be used to develop ACT’s medical devices with a focus on moving the Occlusion Perfusion Catheter (OPC), an intravascular agent delivery device, to out-licensing, as well as working capital and general corporate purposes.

ACT CEO Paul Fitzpatrick said they are thrilled with the positive reception ACT found in Chattanooga, and they are in the process of moving their headquarters to Main Street in Chattanooga as a result of their new partnerships.

"The funding will accelerate progress with the commercialization of the OPC while also facilitating development of some of the other technologies in our pipeline," Fitzpatrick said.